{"id":10013,"date":"2022-11-14T10:30:00","date_gmt":"2022-11-14T09:30:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/"},"modified":"2022-11-14T10:30:00","modified_gmt":"2022-11-14T09:30:00","slug":"irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/","title":{"rendered":"IRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

\n

G\u00f6teborg, Sverige, 14 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att bolaget deltar p\u00e5 LSX Inv\u20ac$tival Showcase som h\u00e5lls i London, Storbritannen. Eventet \u00e4r en del av Europas st\u00f6rsta vecka dedikerad till investeringar inom biotech, l\u00e4kemedel och sjukv\u00e5rd.<\/strong><\/p>\n<\/div>\n

\n

IRLAB kommer att delta p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien, den 14 november 2022. Eventets huvudsakliga syfte \u00e4r att koppla samman chefer inom life science och healthcare med kapital och partners och inkluderar presentationer och personliga m\u00f6ten. Eventet har ett exklusivt partnerskap med den globala investeringsbanken Jefferies, d\u00e4r detta fungerar som f\u00f6rdagen till Jefferies London Healthcare Conference.<\/p>\n<\/div>\n

\n

F\u00f6r mer information:<\/strong><\/p>\n

\n

Richard Godfrey, VD
Telefon: +46 730 70 69 00
E-mail:\u00a0richard.godfrey@irlab.se<\/a><\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

\n

IRLAB uppt\u00e4cker och utvecklar nya l\u00e4kemedel f\u00f6r behandling av Parkinsons sjukdom och andra sjukdomar i hj\u00e4rnan. Bolagets l\u00e4ngst framskridna l\u00e4kemedelskandidater, mesdopetam (IRL790) och pirepemat (IRL752) \u00e4r b\u00e5da i Fas IIb och \u00e4r designade f\u00f6r att behandla n\u00e5gra av de sv\u00e5raste symtomen relaterade till Parkinson. \u00c5r 2021 f\u00f6rv\u00e4rvade Ipsen, ett specialty pharma-bolag, de exklusiva globala r\u00e4ttigheterna till utveckling och kommersialisering av mesdopetam.
\u00a0
IRLAB har genererat alla sina l\u00e4kemedelskandidater och forts\u00e4tter att uppt\u00e4cka innovativa l\u00e4kemedelskandidater f\u00f6r behandling av neurologiska sjukdomar genom den egenutvecklade forskningsplattformen ISP (Integrative Screening Process). F\u00f6rutom IRLAB:s starka kliniska pipeline driver bolaget tv\u00e5 prekliniska program, IRL942 och IRL757, mot Fas I-studier. IRLAB \u00e4r noterat p\u00e5 Nasdaq Stockholm. Mer information p\u00e5\u00a0www.irlab.se.<\/a><\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

IRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien<\/a><\/p>\n<\/div>\n

[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"

G\u00f6teborg, Sverige, 14 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att bolaget deltar p\u00e5 LSX Inv\u20ac$tival Showcase som h\u00e5lls i London, Storbritannen. Eventet \u00e4r en del av Europas st\u00f6rsta vecka dedikerad till investeringar inom biotech, l\u00e4kemedel och sjukv\u00e5rd.<\/p>\n","protected":false},"template":"","class_list":["post-10013","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nIRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg, Sverige, 14 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att bolaget deltar p\u00e5 LSX Inv\u20ac$tival Showcase som h\u00e5lls i London, Storbritannen. Eventet \u00e4r en del av Europas st\u00f6rsta vecka dedikerad till investeringar inom biotech, l\u00e4kemedel och sjukv\u00e5rd.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/\",\"name\":\"IRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2022-11-14T09:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien - IRLAB","og_description":"G\u00f6teborg, Sverige, 14 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att bolaget deltar p\u00e5 LSX Inv\u20ac$tival Showcase som h\u00e5lls i London, Storbritannen. Eventet \u00e4r en del av Europas st\u00f6rsta vecka dedikerad till investeringar inom biotech, l\u00e4kemedel och sjukv\u00e5rd.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/","name":"IRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2022-11-14T09:30:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-lsx-invetival-showcase-i-london-storbritannien\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB deltar p\u00e5 LSX Inv\u20ac$tival Showcase i London, Storbritannien"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/10013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=10013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}